Rhabdoid Tumor of the Kidney
8
0
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Study of Kidney Tumors in Younger Patients
Studying Biomarkers in Samples From Younger Patients With Kidney Cancer
Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor